神经保护剂联合再灌注治疗急性缺血性脑卒中的研究进展  

Recent advance in neuroprotectants combined with reperfusion in acute ischemic stroke

作　　者：谷亚伟[1] 楚旭 李强[1] 范宏光[1] 董银华[1] 王利军[1] 陈念 Gu Yawei;Chu Xu;Li Qiang;Fan Hongguang;Dong Yinhua;Wang Lijun;Chen Nian(Department of Neurology,Tianjin Fourth Central Hospital,Tianjin 300140,China;Medical Department,Xushui District People's Hospital of Baoding,Baoding 072550,China;Department of Neurology,Ninghe District Hospital of Tianjin,Tiaijin 301500,China)

机构地区：[1]天津市第四中心医院神经内科,天津300140 [2]保定市徐水区人民医院内科,保定072550 [3]天津市宁河区医院神经内科,天津301500

出　　处：《中华神经医学杂志》2024年第3期291-295,共5页Chinese Journal of Neuromedicine

基　　金：天津市卫生健康科技项目(ZC20073);天津市第四中心医院2022年度优秀青年人才培养基金(tjdszxyy20220012)。

摘　　要：急性缺血性脑卒中(AIS)是一种严重威胁人类健康和生命的中枢神经系统疾病。目前AIS的一线治疗策略是再灌注治疗。然而,再灌注治疗狭窄的时间窗限制了其在临床的应用率,且相当一部分时间窗内的AIS患者再灌注治疗后并不能达到预期的效果,同时再灌注治疗的相关并发症尚未完全解决。目前一些临床试验证实,神经保护剂是再灌注治疗的有益补充和辅助治疗。本文围绕神经保护剂联合再灌注治疗AIS的研究进展进行综述,以期为AIS的治疗方式改进提供参考。Acute ischemic stroke(AIS)is a kind of central nervous system disease that seriously threatens human health and life.Current treatment for AIS is mainly reperfusion.However,the time-sensitive of reperfusion limits its clinical application,and a considerable part of patients within the time window cannot achieve the expected effect after reperfusion;related complications of reperfusion have not been completely solved.So far,some clinical trials have confirmed that neuroprotectants are useful supplements and adjuncts to reperfusion.This paper reviews the recent advance in neuroprotectants combined with reperfusion in AIS to provide references for AIS treatment.

关 键 词：缺血性脑卒中 再灌注治疗 神经保护剂 

分 类 号：R743.3[医药卫生—神经病学与精神病学]